Jane J Hand, MD
Endocrinology · New York
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 7 years
- Rutgers New Jersey Medical School, 2019
Offices
1 location · Icahn School of Medicine at Mount Sinai · 2,809 clinicians in this group
Looking this up.
Hospitals listed: Mount Sinai West. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hand’s office at (212) 523-8672 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Mount Sinai WestNew York, NYAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Mount Sinai Health System, which runs 5 hospitalsPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — SSI - Abdominal Hysterectomy: 3.906, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.255, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.44, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.125, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.18, Oct 2024 – Sep 2025
See every measure and the patient survey for Mount Sinai West
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 7 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Abdominal HysterectomyInfections | 3.906 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.255 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.44 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.125 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.18 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.69 (0 to 1.57) · 1,716 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.92 (0.69 to 1.15) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.16 (120.66 to 201.66) · 127 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 93 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.1 · 445 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 606 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 475 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.3 · 6,933 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.31) · 11,583 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.4) · 11,501 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.16 (0.52 to 3.81) · 3,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.36 to 3.23) · 1,414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.78 (0.58 to 2.99) · 3,054 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.12 (4.94 to 15.3) · 1,380 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.93 (3.99 to 9.87) · 1,410 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 0.83) · 9,507 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 586 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.809 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.1 · 237 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 1,239 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.7 · 102 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 28.1 · 508 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 17.7 · 601 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.5 · 1,079 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.6 to 7.9) · 99 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (7 to 13.3) · 99 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.6 · 580 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.2 · 149 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.5 · 322 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.3 (9.5 to 16) · 1,088 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 868 cases | No different | Jan 2024 – Dec 2024 |
What patients said (450 patients answered, 13% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 71% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 59% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 67% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Drugs they prescribed that Part D paid
$288,557
Pharmacies billed $288,557 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 679) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
226 generic and 373 brand-name prescriptions · $288,557 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 77 | $75,329 | $978 |
| Mounjaro | 48 | $58,447 | $1,218 |
| Jardiance | 64 | $55,567 | $868 |
| Januvia | 26 | $22,285 | $857 |
| Tresiba Flextouch U-100 | 11 | $4,517 | $411 |
See all 19 drugs
| Ozempic | 77 | $75,329 | $978 |
| Mounjaro | 48 | $58,447 | $1,218 |
| Jardiance | 64 | $55,567 | $868 |
| Januvia | 26 | $22,285 | $857 |
| Tresiba Flextouch U-100 | 11 | $4,517 | $411 |
| Basaglar Kwikpen U-100 | 12 | $3,590 | $299 |
| Novolog Flexpen | 13 | $3,402 | $262 |
| Admelog Solostar | 17 | $2,110 | $124 |
| Lantus Solostar | 15 | $1,521 | $101 |
| Ultra-Fine Short Pen Needle | 17 | $1,020 | $60 |
| Insulin Lispro Kwikpen U-100 | 12 | $1,016 | $85 |
| Ultra-Fine Mini Pen Needle | 14 | $916 | $65 |
| Levothyroxine | 33 | $490 | $15 |
| Hydrocortisone | 15 | $415 | $28 |
| Metformin Hcl Er | 38 | $351 | $9 |
| Atorvastatin | 16 | $188 | $12 |
| Methimazole | 20 | $184 | $9 |
| Glipizide Er | 12 | $144 | $12 |
| Metformin | 28 | $92 | $3 |
Year by year
| 2024 | 679 | 125 | 0% (0) | 55% | $288,557 |
| 2023 | 208 | 45 | 0% (0) | 66% | $127,781 |
| 2021 | 28 | 11 | 0% (0) | None | $3,755 |
| 2020 | 82 | 28 | None | 32% | $9,435 |
| 2019 | 35 | 15 | 0% (0) | None | $2,349 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ozempic | 44 | $46,246 | $1,051 |
| Jardiance | 17 | $15,002 | $882 |
| Novolog Flexpen | 21 | $13,222 | $630 |
| Metformin | 21 | $167 | $8 |
2020: 1 drug
| Eliquis | 13 | $4,109 | $316 |
Money from drug and device companies
$63 in 2025
| 2025 | 1 | 2 | None | $63 |
| 2024 | 1 | 1 | None | $125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer Healthcare Pharmaceuticals | Kerendia | $63 | 2 payments
|
See all 2 published payments
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-27 | Kerendia | $32 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-17 | Kerendia | $31 |
See earlier years (2024)
2024: $125
| Corcept Therapeutics | Korlym | $125 | 1 payment
|
Professional record
- NPI
- 1285195701
- Licence
- NY 316219
- Trained
- Rutgers New Jersey Medical School, 2019 · 7 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 1 Gustave L Levy Pl # 1118, New York, NY, 10029
- NPI first listed
- 2019-03-27
- NPI last updated
- 2025-07-01
- NPI record certified
- 2025-07-01
This is when the NPI record was last certified, not a medical board exam.